An Open-label, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LYN-163 in Healthy Volunteers
Latest Information Update: 26 Jun 2022
At a glance
- Drugs Ivermectin (Primary)
- Indications Malaria
- Focus Adverse reactions
- Sponsors Lyndra
Most Recent Events
- 09 Jun 2022 According to a Lyndra Therapeutics media release, first patient has been dosed in this study.
- 09 Jun 2022 Status changed from not yet recruiting to recruiting, according to a Lyndra Therapeutics media release.
- 16 Sep 2021 New trial record